CAMBRIDGE, Mass., Oct. 3, 2018 /PRNewswire/ — BlueRock Therapeutics, LP, an engineered cell therapy company focused on leveraging its novel Cell+Gene platform to develop regenerative medicines for intractable diseases, announced today that Dr. Emile Nuwaysir, the Company’s President and Chief Executive Officer, has been elected […]
BlueRock Therapeutics, LP, an engineered cell therapy company focused on leveraging its novel Cell+Gene platform to develop regenerative medicines for intractable diseases, today announced its participation in the Cell & Gene Meeting on the Mesa, to be held Oct. 3-5 in La Jolla, Calif.
Appointment strengthens the leadership team and accelerates the company’s establishment of its novel Cell+Gene platform CAMBRIDGE, Mass., Sept. 20, 2018 – BlueRock Therapeutics, LP, an engineered cell therapy company focused on leveraging its novel Cell+Gene platform to develop regenerative medicines for intractable diseases, today announced […]
Company Receives $1 Million Incentive Through Economic Development Initiative of New York State and Empire State Development NEW YORK and CAMBRIDGE, Mass., April 17, 2018 — BlueRock Therapeutics, which is developing cell-based therapies designed to alter the course of degenerative disease, today announced the establishment […]
CAMBRIDGE, Mass., Dec. 1, 2017 — BlueRock Therapeutics today announced the appointment of Derek Hei, Ph.D., as senior vice president, manufacturing, quality and regulatory. “We are thrilled to have Derek join our team. He is a strategic leader with extensive experience in cell and gene […]
NEW YORK and CAMBRIDGE, Mass., Nov. 1, 2017 — BlueRock Therapeutics, a company developing cell-based therapies designed to alter the course of degenerative disease, today announced that its president and chief executive officer, Emile Nuwaysir, Ph.D., has been appointed to The Alliance for Regenerative Medicine […]
CAMBRIDGE, Mass., Oct. 26, 2017 — BlueRock Therapeutics, a company developing cellbased therapies designed to alter the course of degenerative disease, today announced the establishment of its corporate headquarters in Cambridge, Massachusetts, as well as the appointment of senior level team members who will support […]
CAMBRIDGE, MA and SEATTLE, WA, October 3, 2017 – BlueRock Therapeutics and Universal Cells Inc. today announced that they have entered into a collaboration and license agreement to create induced pluripotent stem (iPS) cell lines useful for the manufacture of allogeneic cellular therapies. “BlueRock is […]
Formalizes collaborations with McEwen Center for Regenerative Medicine at University Health Network, Centre for Commercialization of Regenerative Medicine Appoints Michael Scott, Ph.D., as Senior Vice President of Product Development and Toronto Operations TORONTO, Ontario and CAMBRIDGE, Mass., August 17, 2017 — BlueRock Therapeutics, which is […]
CEO, CTO and VP of Corporate Development appointments to propel BlueRock’s cell therapy development efforts CAMBRIDGE, Mass., June 27, 2017 — BlueRock Therapeutics today announced a trio of hires that bolster the company’s strategic and operational capabilities to develop breakthrough cell therapies for degenerative diseases […]
